In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Victor Diaz, Co-Founder of Solitek. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Victor, covering: Falling in love with medicinal chemistry and ending up experiencing the culture shock of North East England! Why Victor fell in love with working on a variety of projects at CROs/CDMOs The benefits of solid state chemistry and its value in pre-clinical formulation development The starting story of Solitek and the decision not to take the easier path to becoming consultants His views on the market outlook and how the application of AI will impact the development pathway Victor obtained his Ph.D. in Organic Chemistry from the University of Seville in 1998 before moving to the UK, where he built most of his professional career. Originally trained as a synthetic and medicinal chemist, he began his career at High Force Research and Medivir. He later transitioned from drug discovery to early development, marking the start of his journey in solid-state science at Pharmorphix. There, he progressed to Projects Director and later Site Manager, playing a key role in the company’s acquisition by Johnson Matthey from Sigma-Aldrich. Victor then spent five years as Head of Physical Sciences at Almac, leading one of the largest solid-state teams in Europe and providing pharmaceutical companies with expert support in crystallisation, polymorphism, and material characterisation. After more than 20 years in the UK, Victor returned to Spain to co-found Solitek, continuing his mission to deliver solid-state and preclinical development services to the pharmaceutical and biotech industries. He currently serves as Operations Director, driving the company’s growth and innovation in the field. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jeremie Trochu, CEO at Ardena. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeremie, covering: The value of hitting the road and getting in front of clients, helping build several career-critical skills The big decision to leave med-tech giant GE and move to an ambitious, growing CDMO called...Catalent How the stars aligned to move back to Europe and join Ardena as CEO...and the secret sauce behind its suite of integrated development capabilities A transformational acquisition of Catalent's Somerset, NJ facility to help take Ardena to the next level as a global CDMO The importance of remembering that we are part of a cyclical industry and must ride out the lows, but we must remain adaptive and bullish about the market's growth Why VUCA (volatility, uncertainty, complexity, ambiguity) is inevitable Jeremie joined Ardena as Chief Executive Officer in June 2024. He brings an extensive knowledge of the life sciences and CDMO industry and a proven track record of success in the biopharma sector. He has 20 years of experience building and growing businesses globally, expanding into new markets, and leading large-scale transformations in publicly traded and privately held companies.  Jeremie was previously part of the team that helped transform Catalent from a private equity spinoff into a publicly traded global CDMO. During his tenure there, he led multiple companies' successful acquisitions and integrations. He holds a master's degree in Business Administration from EMLyon, France. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Rob Wood, pharma portfolio investor and Founder. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Rob, covering: Identifying a niche in the pharma services space that led to working with top 50 Big Pharma Growing STEM into an international powerhouse before eventually selling to UDG Healthcare Life as a pharma portfolio advisor and investor of seven pharma services companies Creating an academy that will introduce entrepreneurship to hundreds of thousands of kids How AI will impact the commercialization of new and existing drugs Rob Wood is an experienced entrepreneur in the pharma services industry. He founded, scaled, and sold STEM for €120 million, expanding into 51 countries and working with all of the top 50 pharmaceutical companies. STEM grew to over 1,000 staff globally and received the Queen's Award for International Trade. After selling STEM, Rob joined UDG plc as CEO & President of Advisory and Head of Group Business Development, leading multiple healthcare consultancies and re-modelling business development across 28 companies. Today, Rob serves as Chairman or Non-Executive Director for several healthcare service companies, focusing on growth, leadership, and investment opportunities. He holds an MBA from Newcastle University. He recently founded the Rob Wood Enterprising Futures Academy in conjunction with Newcastle University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jon Alberdi, CEO at VIVEbiotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering: Falling in love with the world of management and its role in influencing people and society Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space? His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize The before and after of a PE deal with Ampersand - speed, challenge, and intensity Riding the growth of CAR-T products, and which therapy areas are driving demand Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN, where he held several financial controlling roles, including the R&D department at the worldwide product development centre. He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Philip Lee, CEO at GeneFab. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Philip, covering: The role of luck in the development of his entrepreneurial journey of multiple biopharma start-ups Bootstrapping a biological tech company and then selling to Millipore, along with lessons learnt from a more prominent global organization Building a new company from the back of a napkin to an IPO on the NASDAQ Creating a technology platform and operational capability with real therapeutic application that led to the spin-out of Genefab Bridging the gap for early-stage cell therapy companies with aligned incentives and a non-transactional model Philip Lee is a bioengineer, biotechnology entrepreneur, and executive who has spent the last 20 years building companies and commercializing products, including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and advanced manufacturing services. He has been the “first employee” at multiple ventures with leadership experience across diverse growth trajectories, including bootstrapping, VC and PE funding rounds, IPO, acquisition, and internal innovation within a large enterprise. Philip holds degrees from the Massachusetts Institute of Technology and the UC Berkeley/UCSF Joint Graduate Program in Bioengineering. Philip is currently the founding CEO of GeneFab, a contract research, development, and manufacturing organization focused on supporting its clients in bringing innovative genetic medicines to needy patients.  Before GeneFab, Philip was the Co-Founder and CTO of Senti Biosciences, a cell and gene therapy company applying gene circuit technology to improve the efficacy and safety of cancer cell therapies. Philip was also the co-founder and CEO of Cellasic Corp, a microfluidics instrumentation company that MilliporeSigma had acquired. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jodi Cook PhD, President and CEO at Skylark Bio. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering: How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients? Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark. Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics, overseeing its $1 billion acquisition. She earned her Ph.D. from Arizona State University, a Master’s in Audiology from the University of South Carolina, and a Bachelor of Arts from Loyola University Maryland. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals and was previously Board Chair of STRM.BIO. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julien Laizé, Director External Manufacturing CTM at Valneva. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering: Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification... Why the selection process is becoming more and more challenging for buyers The importance of reputation and track record for CDMOs, and the value of being known as a specialist How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?   Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers, Novo Nordisk and Eli Lilly before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason C. Foster, Chief Executive Officer and Executive Director at Ori Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering: How being frustrated by big company life led to the development of a business unit within Reckitt Benckiser that went on to be valued at $1bn The story of how a spin-out went on to list on the LSE with a cool $3.5bn market cap Taking his skills and experience before making 18+ healthcare start-up investments,... determined to add value beyond the cash Being wowed by the potential of CGTs and building the business he always wanted to work for in Ori The mission is to build enabling technology for power cell therapy companies and cut down the manufacturing costs by at least 50% to improve accessibility and affordability. Jason has held leading roles in consulting, healthcare and technology companies for over 20 years in the US, UK and Europe. He is CEO and Executive Director for Ori Biotech, a cell and gene therapy manufacturing technology start-up with offices in London and New Jersey. He raised a $100M Series B funding round in December 2022. Jason also serves as a Non-Executive Director of London-based health tech start-ups gripAble and Credentially and Auxita Pty, an Australian healthcare data platform. As the Managing Director of Health Equity Consulting, he has advised PE/VC funds, family offices, accelerators and healthTech start-ups.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ben Locwin, Chief Scientist, Head of Clinical Services and Project Sciences at Black Diamond Networks (BDN). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering: Being part of the Lonza growth story in its 'scrappy' years Learning never to say no to a good opportunity and how that's opened many doors Becoming part of the more significant patient conversations at Biogen Dropping in seal teams to help companies do what they may never have achieved Why is change always inevitable in our sector, and what may the future hold for us all? As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends. He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant. He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Matthew Bio, CSO, Cambrex & President, Snapdragon Chemistry Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Matt, covering: The frustrating experience of not having ownership or being hands-on at big pharma middle management Recounting the early days of Snapdragon Chemistry and being in the right place at the right time to harness continuous process manufacturing Getting out of the way of your talented people to let them explore and shine The story behind how a proposed acquisition by Asymchem was blocked by the Treasury’s Committee on Foreign Investment in the United States (CFIUS)... Deciding to choose and stay at Cambrex post-acquisition, and having the freedom to use Snapdragon as a catalyst for growth Matt began his career in chemistry more than 30 years ago developing continuous processes for the manufacture and purification of acrylates at the former Rohm & Haas company. Matthew then moved to Columbia University and earned a PhD in Chemistry. Upon graduating, Matthew returned to industry as a process development chemist at Merck Research Laboratories.  In 2006, Matthew moved to Amgen where he worked on the development of both batch and continuous manufacturing solutions for synthetic drug substances. He also worked on the development of new manufacturing technologies for synthetic – biologic hybrid molecules. In 2015, Matthew was a founding member Snapdragon Chemistry, Inc., a contract development firm specialized in continuous manufacturing technology. He is author or inventor on more than 30 peer-reviewed publications and patents, and numerous regulatory filings. Matthew is driven by a passion for the development of new chemical technologies. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sara Tylosky, CEO at Farmacon Global. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sara, covering: The gift and curse of being known for rescuing complex clinical trials The data challenge of rare diseases and how that impacts patient access Navigating the complexity of rare diseases in Latin America and why it all starts with education How her father's role in building space stations globally inspired her own international business journey The future of clinical trials and why Latin America is well positioned to be a leading player Sara brings over 20 years of experience leading teams in both large and small pharmaceutical and biotech environments. She has led Farmacon Global, a strategic CRO of medical consultants, in accelerating clinical trials, increasing diversity, supporting enrollment, and paving the way to market access in emerging markets. Known for her high cultural intelligence and problem-solving skills, Sara and her team specialize in Rare Diseases, Immunology, Infectious Diseases, Cancer, and Vaccines. Fluent in Spanish and having lived on four continents, she has a special focus on Latin America while actively expanding into other key markets globally. Sara's direction plays a pivotal role in steering Farmacon Global toward healthcare innovation and global market leadership. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ray Pressburger, Senior Managing Director, Accenture Strategy - Lead for Life Sciences and US Market Products Industries. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ray, covering: Continuously making mistakes as an authentic leader, and his journey across two decades at Accenture The five most important themes for CEOs of the 10 big pharma firms... The dominant question of our moment... and an underappreciated issue going under the radar How AI and tech give us a chance to reimagine and rebuild from the ground up Ray has 20 years of experience in strategy, growth, and transformation in the Life Sciences industry. He specializes in helping C-suite leaders navigate business unit and portfolio strategies, commercial model changes, and growth initiatives. Passionate about the evolving economic landscape, Ray works internationally, driving impactful change and innovation for clients in North America, Europe, and emerging markets. He holds a degree in Information and Systems Engineering from Lehigh University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Luke Bilton, Co-Founder at Life Science Networks, PharmaSource and CDMO Live. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Luke, covering: How Covid exposed the complacency of event organizers in pharma services Behind the scenes of organizing CPHI Worldwide - what's it really like - chaos or calm? How companies should be thinking about event budgeting, planning and ROI in 2025 Beware 'the HIPPO' when planning which events to attend Luke Bilton is Co-Founder of Life Science Networks, a next-generation community and events organization specializing in biopharma manufacturing. The company's growing portfolio includes the PharmaSource outsourcing podcast and online community, alongside its flagship event, CDMO Live. With over 20 years experience launching and growing digital media and events businesses at companies including Informa, Future and Innovation Enterprise, Luke partnered with Chris Kilbee, former head of CPHI global events, to establish Life Science Networks. CDMO Live (World Trade Center, Rotterdam, 7-8 May 2025) brings together biopharma's manufacturing leaders to optimize their outsourcing strategy. The event's unique PartnerMatch program facilitates curated one-to-one meetings between sponsors and over 50 leading CDMOs. To find out more, visit CDMO Live Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering: Stretching yourself by tapping into the collective wisdom of others The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin). He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering: His unusual blend of experience led to a road into big pharma... Switching the security of Big Pharma to join an exciting, scrappy, start-up biotech... before an exit to Roche Being part of the gene therapies evolution with an innovative biotech that later became Novartis Gene Therapies His views on the thorny issue of CGT products' price (and value) Opting to start his own business aimed at supporting the future of healthcare Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry. As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.    Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering: How a family-owned pharmacy became a major global clinical trial supplies business... two generations later Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success James' decision to take on the baton and fuel organic and inorganic growth through client-centricity The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook Why this industry will always grow due to unmet medical needs and breakthroughs in science Michael’s passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university’s Katz Graduate School of Business. James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter DeYoung, CEO at Piramal Global Pharma. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering: Why did Peter fall in love with the pharma sector? Why did he decide to leave McKinsey and jump into PE? The value of living and working in different places, and why you should jump at the chance if you ever get the opportunity to do it Avoiding the 'peanut butter strategy' and divesting non-core activities to prioritize truly Piramal's secret sauce of differentiating 'magnets' that attract new clients, and the importance of genuinely listening to customers The elements that make India such a superpower drive the belief that 'this is India's century' Supply chain security and resiliency, 'friend-shoring' and onshoring, and preparing for uncertainty and change Peter DeYoung is Piramal Global Pharma's CEO, comprising Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses. Before this, he spearheaded several leadership mandates at the Piramal Group, including the CEO of Piramal Critical Care and the President of Life Sciences. Previously, Peter worked in various investing and consulting roles in healthcare in the USA, Europe and India. After graduating from Princeton, he joined McKinsey & Company in New York, where he worked on several projects for pharmaceutical and medical device companies. Later, he joined the Blackstone Group’s Private Equity Division in Mumbai, where he was part of the deal team for several significant transactions across a broad spectrum of industry sectors in India. Peter holds a Master’s Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ian Tzeng, a Managing Director and Partner in L.E.K. Consulting. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering: Reflections on 2024's market dynamics, shifting sponsor behavior, big pharma woes, biotech rebound and segment-specific impact The outlook for 2025 across discovery, development, clinical trials, and manufacturing The uptick Ian expects and where companies should be focusing efforts Ian Tzeng, a Managing Director and Partner in L.E.K.’s Boston office, joined the company in 1998 with experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He focuses on healthcare and life sciences, including pharmaceuticals, vaccines and medical devices.    He leads L.E.K.’s Pharmaceutical Contract Services practice, including CROs, CDMOs, supply chain and distribution, commercial, medical, and market access services. Other areas of deep experience include rare diseases, biodefense, biosimilars and generics, and consumer-directed healthcare.  Additionally, Ian has extensive consulting and board experience with nonprofit organizations in education, arts, LGBT advocacy and public service. He received a Bachelor of Arts degree, magna cum laude, in chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal, Founder & Global President at ramarketing & Host of Molecule to Market. For this milestone episode, your host is Molecule to Market’s first guest from back in 2020, JoyL Silva, Customer Engagement Lead for the US Primary Care portfolio at Pfizer, who discusses the pharmaceutical and biotechnology supply chain with Raman Sehgal covering: Raman reflects on the podcast’s evolution, from its inception during COVID-19 to becoming a globally recognized platform They discuss key trends in the pharma outsourcing sector and the impact of guests who have contributed to the podcast’s success Raman shares highlights from his career, including the growth of his companies, ramarketing and Lead Candidate, and his private equity ventures Insights into balancing work and family life, with advice on being present and managing priorities A desert island question where Raman chooses which podcast guests he’d bring along, plus behind-the-scenes stories of challenges and humorous incidents JoyL Silva is the Customer Engagement Lead for Pfizer’s US Primary Care portfolio, overseeing sales and account management across therapeutic areas such as Migraine, Cardiovascular, Anti-virals, and Vaccines. She leads high-performing teams that drive a $20B portfolio through agile methodologies and talent development. With over 20 years at Pfizer, JoyL has excelled in commercial leadership, business transformations, and operational expertise, delivering impactful results across multiple roles, including VP for Hematology and Biosimilars, General Manager of Pfizer CentreOne, and US/Global Commercial Lead for PAXLOVID, where she spearheaded global strategies and partnerships for Pfizer’s COVID-19 antiviral therapeutic. JoyL frequently speaks at industry forums and contributes her expertise to various publications and professional boards, including the Pharma & Biopharma Outsourcing Association. Her accolades include being named to the Medicine Maker Power List and PharmaVOICE 100 Most Inspiring People in the Life Sciences Industry, as well as receiving awards such as the Scrip Best Partnership Alliance Award and Putnam Media Top 20 Influential Women in Manufacturing. Her career reflects a strong commitment to driving innovation and fostering leadership in the life sciences sector. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!    Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.